DUBLIN, September 28, 2023 (GLOBE NEWSWIRE) — “European Recombinant Protein Manufacturing Services Market Size, Share and Trend Analysis Report” By Service Type (Preclinical & Clinical), By Host Cell (Mammalian, Bacterial); Added ‘Usage, Country and Segment Forecast, 2023-2030’ report by end ResearchAndMarkets.com Recruitment.
The European recombinant protein manufacturing services market size is expected to reach USD 3.26 billion in 2030 and is expected to grow at a CAGR of 14.88% from 2023 to 2030.
Recombinant proteins have many applications in the fields of biotechnology research and medicine. Furthermore, recombinant protein production is one of the effective procedures utilized in the life sciences field and has a significant impact on advanced medicine.
Proteins are modified using specific procedures to produce recombinant proteins. These recombinant proteins are genetically encoded, produce large amounts of protein, and are used to manufacture therapeutic products. Government initiatives and increased investment in the life sciences sector are likely to facilitate the expansion of Europe’s recombinant protein manufacturing services industry.
Additionally, the increasing demands and complexity of manufacturing regulations and the increasing cost of maintaining GMP certification on-site are driving the adoption of outsourced manufacturing and packaging models. Outsourcing also allows companies to free up capital and reduce overhead costs. Additionally, UK biotech companies outperform their European peers in securing early-stage funding. From 2018 to 2020, biotech startups in the country raised $3.6 billion, a 20% increase compared to the amount raised from 2015 to 2017. As a result, the country’s research and development services landscape is expected to experience significant growth in the coming years. Ten years.
In Europe, several major companies, including Lonza, offer recombinant protein production services. Genscript. Partnerships with companies such as Merck KGaA; Kaneka Eurogentec SA; ExcellGene SA. create growth prospects for outsourcing activities. The region’s leading companies are expanding their manufacturing capacity to meet Europe’s growing demand for outsourcing.
For example, in October 2022, Merck KGaA opened a new commercial facility for Millipore CTDMO services in Martillac, France. New 2,700 sqm. Facilities were built to produce drug substances, including monoclonal antibodies and other recombinant proteins. Similarly, Fujifilm acquired Biogen’s Denmark-based biologics manufacturing site in August 2019 for approximately $890 million. Such initiatives are expected to create lucrative growth opportunities for the recombinant protein manufacturing services industry over the next decade.
Although the existence of strong regulations helps protect patient health and safety, it can lead to approval delays, high manufacturing costs, and compliance challenges that hinder the development of recombinant protein-based products. , which could limit the growth of manufacturing services.
European Recombinant Protein Manufacturing Services Market Report Highlights
- By service type, the commercial production services sector accounted for the largest share of 58.82% in 2022. This is due to the increased accessibility of high-yield expression systems.
- By host cell, the mammalian segment accounted for the largest share of 54.70% in 2022.Market is expanding due to increasing demand for mammalian cells from pharmaceutical and biotech companies
- By end use, the pharmaceutical and biotechnology companies sector accounted for the largest share of 78.79% in 2022. Recombinant proteins are attracting significant attention in the biotechnology and pharmaceutical industries and can be used to develop vaccines and treatments for a variety of diseases and proteins.manufacturing services
- Germany accounted for a large share of total revenue in 2022. This is primarily due to the presence of major market players, rising research expenditures, and availability of established medical infrastructure driving market growth across the region.
|number of pages||98|
|Estimated market value in 2022 (USD)||$1.06 billion|
|Projected market value to 2030 (USD)||$3.26 billion|
|compound annual growth rate||14.8%|
Main topics covered:
Chapter 1 Methodology and Scope
1.1. Market segmentation and scope
1.2. Market definition
1.3. Research assumptions
1.4. Information procurement
Chapter 2 Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshots
2.3. Snapshot of the competitive environment
Chapter 3 Market Variables, Trends, and Scope
3.1. Market system outlook
3.1.1. Parent market outlook
3.1.2. Related/Supplementary Market Outlook
3.2. Market trends and outlook
3.3. Market trends
3.3.1. Increased adoption of outsourcing models in recombinant protein production
3.3.2. Expanding the range of applications for recombinant protein-based products
3.3.3. Increased use of recombinant proteins in research activities
3.4. Market restraint analysis
3.4.1. Strict regulations related to recombinant protein-based biopharmaceuticals
3.5. Business environment analysis
3.5.1. SWOT analysis; by factor (political/legal, economic/technical)
3.5.2. Porter’s Five Forces Analysis
3.6. Impact analysis of the new coronavirus infection
Chapter 4 Service-type business analysis
4.1. European Recombinant Protein Manufacturing Services Market: Service Type Trend Analysis
4.2. Preclinical and Clinical Services
4.3. Commercial production services
Chapter 5 Host Cell Business Analysis
5.1. European Recombinant Protein Manufacturing Services Market: Host Cell Movement Analysis
5.2. Mammalian cells
5.3. Bacterial cells
5.4. Insect cells
5.5. Yeast and fungi
Chapter 6 End-use Business Analysis
6.1. European Recombinant Protein Manufacturing Services Market: End-use Transfer Analysis
6.2. Pharmaceutical and biotechnology companies
6.3. Academic research institutions
Chapter 7 Business analysis of each country
7.1. Europe Recombinant Protein Manufacturing Services Market Share by Countries, 2022 and 2030
7.2.1. European Recombinant Protein Manufacturing Services Market, 2018-2030 (USD Million)
Chapter 8 Competitive Environment
8.1. Company classification
8.2. Strategy mapping
8.3. Company profile/list
18.104.22.168. Financial Performance (Net Revenue/Sales/EBITDA/Gross Margin)
22.214.171.124. Product Benchmarking
126.96.36.199. Strategic initiatives
8.3.2. Boehringer Ingelheim International GmbH
8.3.3. Fujifilm Diosynth Biotechnologies
8.3.4. Merck KGaA
8.3.5. Bruker (InVivo BioTech Services GmbH)
8.3.6. Sino Biological Co., Ltd.
8.3.8. Kaneka Corporation (Kaneka Eurogentec SA)
8.3.9. Polyplus transfection (Xpress Biologics)
For more information about this report, please visit https://www.researchandmarkets.com/r/n2ygqx.
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.
European recombinant protein manufacturing services market
#European #Recombinant #Protein #Manufacturing #Services #Market #Trend #Analysis #Report #Increased #Adoption #Outsourcing #Models #Driving #Growth